Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone Metastases
- 12 December 1996
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 335 (24), 1785-1792
- https://doi.org/10.1056/nejm199612123352401
Abstract
Bisphosphonates such as pamidronate disodium inhibit osteoclast-induced bone resorption associated with cancer that has metastasized to bone.Keywords
This publication has 24 references indexed in Scilit:
- Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple MyelomaNew England Journal of Medicine, 1996
- Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking studyCancer, 1994
- Osteoclast inhibition for the treatment of bone metastasesCancer Treatment Reviews, 1993
- The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancerEuropean Journal of Cancer and Clinical Oncology, 1991
- Treatment of Tumor-Induced Osteolysis by APDPublished by Springer Nature ,1989
- Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma.BMJ, 1988
- Primary chemotherapy with mitoxantrone and prednisone in advanced breast carcinoma. A phase II studyEuropean Journal of Cancer and Clinical Oncology, 1988
- Bone metastases and breast cancerCancer Treatment Reviews, 1985
- Chemotherapy in Advanced Breast Carcinoma Comparison Between Doxorubicin-Cyclophosphamide and Cyclophosphamide-Methotrex-Ate-5-Fluorouracil-Vincristine-PrednisoneActa Radiologica: Oncology, 1985
- Measuring the quality of life of cancer patientsJournal of Chronic Diseases, 1981